Načítá se...
First-line treatment options in metastatic renal cell cancer
The introduction of targeted therapy a decade ago revolutionized the treatment of metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian target o...
Uloženo v:
| Vydáno v: | Can Urol Assoc J |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Canadian Medical Association
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215299/ https://ncbi.nlm.nih.gov/pubmed/28096934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.4307 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|